| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.02 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.03 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.03 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.082 | 0.03 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.03 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.075 | 0.04 |